| The first case of COVID-19 treated with the complement C3 inhibitor AMY-101 S Mastaglio, A Ruggeri, AM Risitano, P Angelillo, D Yancopoulou, ... Clinical immunology 215, 108450, 2020 | 295 | 2020 |
| GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study G De Luca, G Cavalli, C Campochiaro, E Della-Torre, P Angelillo, ... The Lancet Rheumatology 2 (8), e465-e473, 2020 | 227 | 2020 |
| Prevalence, characteristics, risk factors, and outcomes of invasively ventilated COVID-19 patients with acute kidney injury and renal replacement therapy EV Fominskiy, AM Scandroglio, G Monti, MG Calabro, G Landoni, ... Blood purification 50 (1), 102-109, 2021 | 117 | 2021 |
| MYD88 L265P mutation and interleukin‐10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous … AJM Ferreri, T Calimeri, P Lopedote, I Francaviglia, R Daverio, C Iacona, ... British Journal of Haematology 193 (3), 497-505, 2021 | 57 | 2021 |
| Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome. GA Ramirez, EP Bozzolo, E Castelli, A Marinosci, P Angelillo, S Damanti, ... Minerva medica 113 (2), 281-290, 2020 | 30 | 2020 |
| Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial AJM Ferreri, T Calimeri, M Ponzoni, F Curnis, GM Conte, E Scarano, ... Blood Advances 4 (15), 3648-3658, 2020 | 26 | 2020 |
| Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse C Rusconi, CY Cheah, TA Eyre, D Tucker, P Klener, E Giné, L Crucitti, ... Blood, The Journal of the American Society of Hematology 140 (17), 1907-1916, 2022 | 23 | 2022 |
| Diagnostic and clinical impact of staging 18F-FDG PET/CT in mantle-cell lymphoma: a two-center experience D Albano, P Ferro, G Bosio, F Fallanca, A Re, A Tucci, AJM Ferreri, ... Clinical Lymphoma Myeloma and Leukemia 19 (8), e457-e464, 2019 | 16 | 2019 |
| Interleukin‐1 receptor‐associated kinase 4 inhibitor interrupts toll‐like receptor signalling and sensitizes chronic lymphocytic leukaemia cells to apoptosis VS Delvecchio, I Sana, ME Mantione, MG Vilia, P Ranghetti, A Rovida, ... British Journal of Haematology 189 (3), 475-488, 2020 | 13 | 2020 |
| Long‐lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B‐cell lymphoma who are not eligible for or failed autologous transplantation AJM Ferreri, M Sassone, P Angelillo, F Zaja, A Re, A Di Rocco, M Spina, ... Hematological Oncology 38 (3), 257-265, 2020 | 11 | 2020 |
| Caring with compassion during COVID-19 S Renzi, F Fallanca, A Zangrillo, M Tresoldi, G Landoni, P Angelillo, ... Palliative & Supportive Care 18 (4), 403-404, 2020 | 9 | 2020 |
| Transcriptional mechanism of vascular endothelial growth factor-induced expression of protein kinase CβII in chronic lymphocytic leukaemia cells O Al-Sanabra, AD Duckworth, MA Glenn, BRB Brown, P Angelillo, K Lee, ... Scientific Reports 7 (1), 43228, 2017 | 9 | 2017 |
| Monoclonal B-cell lymphocytosis: Does the elderly patient need a specialistic approach? P Angelillo, A Capasso, P Ghia, L Scarfò European Journal of Internal Medicine 58, 2-6, 2018 | 8 | 2018 |
| Role of NFAT in chronic lymphocytic leukemia and other B-cell malignancies I Sana, ME Mantione, P Angelillo, M Muzio Frontiers in Oncology 11, 651057, 2021 | 7 | 2021 |
| COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome MT Lupo-Stanghellini, E Xue, S Mastaglio, C Oltolini, P Angelillo, ... Bone Marrow Transplantation 56 (9), 2312-2315, 2021 | 6 | 2021 |
| Safety and efficacy of a dose-dense short-term therapy in patients with MYC-translocated aggressive lymphoma AJM Ferreri, P Angelillo, F Erbella, C Cattaneo, L Verga, A Lleshi, ... Blood Advances 6 (22), 5811-5820, 2022 | 3 | 2022 |
| Prognostic factors, management and outcome of an international series of 41 patients with primary mediastinal large B‐cell lymphoma (PMLBCL) and central nervous system (CNS … AJM Ferreri, V Tarantino, G Cabras, F Ferrara, PL Zinzani, L Arcaini, ... Hematological Oncology 39, 2021 | 1 | 2021 |
| Blood-brain barrier permeabilization with engineered tumor necrosis factor-α followed by R-CHOP is an active and safe salvage therapy in primary CNS lymphoma A Ferreri, T Calimeri, M Ponzoni, F Curnis, GM Conte, E Scarano, ... | 1 | 2020 |
| Clinical Relevance of MYD88 L265P Mutation and Interleukin-10 Level in Cerebrospinal Fluid of Patients with Both Newly Diagnosed and Relapsed Primary Diffuse Large B-Cell … AJM Ferreri, T Calimeri, P Lopedote, I Francaviglia, R Daverio, C Iacona, ... Blood 134, 4114, 2019 | 1 | 2019 |
| Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study A Chiappella, B Casadei, P Chiusolo, A Di Rocco, S Ljevar, M Magni, ... Leukemia, 1-8, 2024 | | 2024 |
